Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer

Clinical trial NCT03257163 · ACTIVE_NOT_RECRUITING

Trial details

NCT number

NCT03257163

Sponsor

Rutgers, The State University of New Jersey

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2017-09-29

Primary completion

2026-08-31

Enrollment

40

View on ClinicalTrials.gov